This study analyzed repeated methylphenidate (MPH) administration and its effects on brain-derived neurotrophic factor (BDNF) in the dorsal striatum and nucleus accumbens of male and female adolescent rats. In Experiment 1, rats were administered intraperitoneal (ip) saline, 1, 3, or 5 mg/kg dose of MPH every second day from postnatal day (P)33–P49. Locomotor activity was analyzed for 10 min after each administration. Results revealed that the 1 mg/kg dose of MPH produced locomotor suppression, however, the 5 mg/kg dose of MPH produced locomotor sensitization and robust behavioral activation in females as compared to males. In Experiment 2, animals were administered ip saline or the 5 mg/kg dose of MPH using an identical regimen but a 30 min behavioral test was employed. Dorsal striatum and nucleus accumbens tissue was assayed for BDNF at P50. Females demonstrated sensitization to MPH and increased locomotor activation compared to males. Interestingly, females given MPH demonstrated a significant 42% decrease of striatal BDNF whereas males administered MPH demonstrated a significant 50.4% increase of striatal BDNF compared to controls. There were no effects on accumbal BDNF. This report demonstrates robust sex differences in the behavioral response, but sex-dependent changes in striatal BDNF in response to MPH in adolescence.
AndersenSLTeicherMH (2000) Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev24: 137–141.
2.
AndersenSLThompsonAPKrenzelE. (2002) Pubertal changes in gonadal hormones do not underlie adolescent dopamine receptor overproduction. Psychoneuroendocrinology27: 683–691.
3.
BanerjeePSAstonJKhundakarAA. (2009) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Eur J Neurosci29: 465–476.
4.
BeckerJB (1999) Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav64: 803–810.
5.
BerridgeCWDevilbissDMAndrzejewskiME. (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry60: 1111–1120.
6.
BibelMBardeYA (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev14: 2919–2293.
7.
BiedermanJFaraoneSVSpencerT. (1994) Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatry Res53: 13–29.
8.
BolañosCANestlerEJ (2004) Neurotrophic mechanisms in drug addiction. Neuromolecular Med5: 69–83.
9.
BoozeRMWelchMAWoodML. (1999) Behavioral sensitization following repeated intravenous nicotine administration: gender differences and gonadal hormones. Pharmacol Biochem Behav64: 827–839.
10.
BrenhouseHCNapierataLKussmaulL. (2009) Juvenile methylphenidate exposure and factors that influence incentive processing. Dev Neurosci31: 95–106.
11.
BrightGM (2008) Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med10: 111.
12.
BrownRWPernaMKSchaeferTL. (2006) The effects of adulthood nicotine treatment on D2-mediated behavior and neurotrophins of rats neonatally treated with quinpirole. Synapse59: 253–259.
13.
BrowneRGSegalDS (1977) Metabolic and experimental factors in the behavioral response to repeated amphetamine. Pharmacol Biochem Behav6: 545–552.
14.
CastnerSAXiaoLBeckerJB (2006) Sex differences in striatal dopamine: in vivo microdialysis and behavioral studies. Brain Res610: 127–134.
15.
ChaseTCarreyNSooE. (2007) Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience2007144: 969–984.
16.
ChelaruMIYangPBDafnyN (2012) Sex differences in the behavioral response to methylphenidate in three adolescent rat strains (WKY, SHR, SD). Behav Brain Res226: 8–17.
17.
DafnyNYangPB (2006) The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull68: 393–405.
18.
DevilbissDMBerridgeCW (2006) Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge. J Pharmacol Exp Ther319: 1327–1335.
19.
Dow-EdwardsD (2010) Sex differences in the effects of cocaine abuse across the life span. Physiol Behav100: 208–215.
20.
DupontRLColemanJJBucherRH. (2008) Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict17: 167–171.
21.
ErnstMLiebenauerLLKingAC. (1994) Reduced brain metabolism in hyperactive girls. J Am Acad Child Psy33: 858–868.
22.
FestaEDRussoSJGaziFM. (2004) Sex differences in cocaine-induced behavioral responses, pharmacokinetics, and monoamine levels. Neuropharmacology46: 672–687.
23.
FilipMFaron-GóreckaAKuśmiderM. (2006) Alterations in BDNF and trkB mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Res1071: 218–225.
24.
FumagalliFCattaneoACaffinoL. (2010) Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res62: 523–529.
25.
GawinFH (1991) Cocaine addiction: psychology and neurophysiology. Science251: 1580–1586.
26.
GerasimovMRFranceschiMVolkowND. (2000) Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther295: 51–57.
27.
GoldmanLSGenelMBezmanRJ. (1998) Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA279: 1100–1107.
28.
GrahamDLEdwardsSBachtellRK. (2007) Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci10: 1029–1037.
29.
GriffithsRRTroisiJRSilvermanK. (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol4: 3–13.
30.
GrillyDMSalamoneJM (2005) Drugs and Human Behavior. Upper Saddle River, NJ: Prentice-Hall.
31.
GrimmJWLuLHayashiT. (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci23: 742–747.
32.
HarrodSBMactutusCFBennettK. (2004) Sex differences and repeated intravenous nicotine: behavioral sensitization and dopamine receptors. Pharmacol Biochem Behav78: 581–592.
33.
HolsonRRPearceB (1992) Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol Teratol14: 221–228.
34.
HorgerBAIyasereCABerhowMT. (1999) Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci19: 4110–4122.
35.
HuangEJReichardtLF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci24: 677–673.
36.
KennyPJFileSERattrayM (2000) Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res Mol Brain Res85: 234–238.
37.
KimkoHCrossJAbernethyD (1999) Pharmacokinetics and clinical effectiveness of methyphenidate. Clin Pharmacokinet37: 457–470.
38.
Klein-SchwartzWMcGrathJ (2003) Poison centers’ experience with methylphenidate abuse in preteens and adolescents. J Am Acad Child Adolesc Psych42: 288–294.
39.
KucenskiRSegalDS (2002) Exposure of adolescent rats to oral methylphenidate: effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci22: 264–271.
MayesRBagwellCErkulwaterJ (2008) ADHD and the rise in stimulant use among children. Harv Rev Psychiatry16: 151–166.
42.
ParranTVJasinskiDR (1991) Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med151: 781–783.
43.
PierceRCKalivasPW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev25: 192–216.
44.
PolanczykGDe LimaMSHortaBL. (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry164: 942–948.
45.
RivestRFalardeauPDi PaoloT. (1995) Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res692: 269–272.
46.
RobinsonTEBeckerJB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res396: 157–198.
47.
RucklidgeJJ (2010) Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am33: 357–373.
48.
SchererEBDa CunhaMJMattéC. (2010) Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol Learn Mem94: 247–253
49.
ScheresAMilhamPMKnutsonB. (2007) Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. Biol Psychiatry61: 720–724.
50.
SchuelkeGSKonkolRJTerryLC. (1996) Effect of cocaine metabolites on behavior: possible neuroendocrine mechanisms. Brain Res Bull39: 43–48.
51.
SchweriMMSkolnickPRaffertyMF. (1985) [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem45: 1062–1070.
52.
SheppardBLehmannJCopeZA. (2009) Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes. Behav Neurosci123: 1296–1308.
SolantoMV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res94: 127–152.
55.
SpearLP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev24: 417–463.
56.
TrippGWickensJR (2009) Neurobiology of ADHD. Neuropharmacology57: 579–89.
57.
VolkowNDSwansonJM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry160: 909–918.
58.
VolkowNDWangGJFowlerJS. (1999) Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sciences65: PL7–PL12.
59.
WalkerQDRooneyMBWightmanRM. (2000) Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry. Neuroscience95: 1061–1070.
60.
WarrenBLIñiguezSDAlcantaraLF. (2011) Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood. J Neurosci31: 10347–10358.
61.
WilensTEBoellnerSWLópezFA. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry47: 21–31.
62.
WootersTEDwoskinLPBardoMT (2006) Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders. Psychopharmacology188: 18–27.
63.
YangPBSwannACDafnyN (2006) Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull200671: 301–310.
64.
ZitoJ (2002) Five burning questions. J Dev Behav Pediatr23(S1): S23–S30.
65.
ZitoJMSaferDJdosReisS. (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA283: 1025–1030.
